Search

Displaying results 1741 - 1750 of 10000 in total
  1. Drug

    Zanubrutinib

    go.drugbank.com/drugs/DB15035
    ApprovedInvestigational

    [A187958] Due to this enhanced selectivity towards BTK, zanubrutinib belongs to the second-generation BTK inhibitor drug group that also includes [acalabrutinib], which was approved by the FDA in 2017. … [A187985] Compared to the first-generation BTK inhibitor [ibrutinib], zanubrutinib displays higher potency and selectivity for BTK with fewer off-target effects.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2B6 InducersProducts: BRUKINSA 80 mg capsules
  2. Drug

    Pentamidine

    go.drugbank.com/drugs/DB00738
    ApprovedInvestigational

    Antiprotozoal agent effective in trypanosomiasis, leishmaniasis, and some fungal infections; used in treatment of pneumocystis pneumonia in HIV-infected patients. It may cause diabetes mellitus, central nervous system damage, and other t...

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesProducts: PENTACARINAT ® 300 MG, DBL PENTAMIDINE ISETHIONATE FOR INJECTION BP 300 mg/vial
  3. Drug

    Penciclovir

    go.drugbank.com/drugs/DB00299
    Approved

    Penciclovir is a synthetic acyclic guanine derivative with antiviral activity used for the treatment of various herpes simplex virus (HSV) infections. Displaying low toxicity and good selectivity, penciclovir is a nucleoside analogue.

    Synonyms: 9-[4-hydroxy-3-(hydroxymethyl)but-1-yl]guanineCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 Substrates
  4. Drug

    Ioxaglic acid

    go.drugbank.com/drugs/DB09313
    ApprovedWithdrawn

    Ioxaglic acid has a low osmolarity and is associated with fewer side effects compared to older contrast agents [L1883].

    Mixtures: Hexabrix 200, Hexabrix 200Products: HEXABRIX 320 INJECTION 320 mgI/ml
  5. Drug

    Hexoprenaline

    go.drugbank.com/drugs/DB08957
    ApprovedWithdrawn

    Hexoprenaline is a stimulant of beta 2 adrenergic receptors. It is used as a bronchodilator, antiasthmatic, and tocolytic agent.

    Products: Gynipral 10 µg/2 ml - Ampullen, Gynipral 25 µg - Konzentrat zur Infusionsbereitung
  6. Drug

    Disperse Blue 106

    go.drugbank.com/drugs/DB14203
    Approved

    Disperse Blue 106 is used in allergenic testing.

    Synonyms: Disperse Blue 106, 5-Nitro-2-(2-methyl-4-(N-ethyl-N-(2-hydroxyethyl)amino)phenylazo)thiazole
  7. Drug

    Rubella virus vaccine

    go.drugbank.com/drugs/DB10317
    ApprovedInvestigational

    Rubella is a common childhood disease, caused by rubella virus (togavirus).

    Mixtures: TRESIVAC 0,5 ML SC ENJEKSIYONLUK ÇÖZELTI IÇIN LIYOFILIZE TOZ IÇEREN FLAKON, 10 ADET, SII MEASLES,MUMPS & RUBELLA VACCINE LIVE ATTENUATED (FREEZE-DRIED) 10 DOSESProducts: R-VAC 0,5 ML SC ENJ. COZ. ICIN LIY. TOZ ICEREN FLAKON
  8. Drug

    Ilaprazole

    go.drugbank.com/drugs/DB11964
    Investigational

    Ilaprazole has been investigated in Helicobacter Infections.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesProducts: NOLTEC 10 MG GASTRO-REZİSTAN TABLET, 56 ADET, NOLTEC 10 MG GASTRO-REZİSTAN TABLET, 7 ADET
  9. Drug

    Iron isomaltoside 1000

    go.drugbank.com/drugs/DB12208
    ApprovedInvestigationalWithdrawn

    Iron isomaltoside 1000 is under investigation in Iron Deficiency Anaemia. … Iron isomaltoside 1000 has been investigated for the treatment and basic science of Anemia, Gastric Cancer, Esophageal Cancer, Chronic Kidney Disease, and Anemia, Iron-Deficiency, among others.

    Synonyms: Iron isomaltoside 1000
  10. Drug

    Gilteritinib

    go.drugbank.com/drugs/DB12141
    ApprovedInvestigational

    [A40036] It is a pyrazinecarboxamide derivative that showed high selectivity to FLT3 preventing the c-Kit -driven myelosuppression observed in other therapies. … [A40044] Gilteritinib was developed by Astellas Pharma and FDA approved on November 28, 2018.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesProducts: XOSPATA 40 MG FİLM KAPLI TABLET, 84 ADET